Liquidia Surges After $381 Million Settlement with United Therapeutics for Lung Disease Drug
The deal ends six lawsuits and leaves Liquidia focused on PAH after it agreed to pay about $380.7 million and drop PH-ILD promotion.
10 Articles
10 Articles
Liquidia surges as United Therapeutics settlement removes key litigation risk - Regional Media News
By Siddhi Mahatole Oct 14 (Reuters) - Liquidia shares jumped 26% on Wednesday after it settled a years-long legal dispute with United Therapeutics over its lung disease drug, removing a major litigation risk for the drugmaker. The settlement, announced late on Tuesday, ends six lawsuits [...]
United Therapeutics and Liquidia Just Ended Their Patent War. Liquidia Stock Popped 42%
A patent court ruling wiped out nearly half of Liquidia's stock value in a single day, and the settlement that followed cost the company almost every dollar it had in the bank. Whether that price was a bargain or a slow bleed depends on one number Liquidia has not yet revealed.
Liquidia surges after $381 million settlement with United Therapeutics for lung disease drug
Oct 14 (Reuters) - Liquidia shares jumped nearly 40% in premarket trading on Wednesday after the drugmaker settled a years-long legal dispute with United Therapeutics over its lung disease drug. The settlement, announced late on Tuesday, ends six laws...
Legal settlement secures long-term access to Yutrepia for PAH
Liquidia and United Therapeutics have entered into a global settlement that ends a yearslong legal dispute over Yutrepia, Liquidia’s dry powder inhalation formulation of the medication treprostinil. Under the settlement, Liquidia will maintain access to Yutrepia for people with pulmonary arterial hypertension (PAH), but pull the therapy from the market as an option for pulmonary […]
Coverage Details
Bias Distribution
- 50% of the sources are Center, 50% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
